Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226,220,429
-
Total 13F shares
-
115,525,619
-
Share change
-
+5,510,336
-
Total reported value
-
$570,761,427
-
Put/Call ratio
-
486%
-
Price per share
-
$4.94
-
Number of holders
-
170
-
Value change
-
+$24,488,348
-
Number of buys
-
84
-
Number of sells
-
68
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q1 2023
As of 31 Mar 2023,
Allogene Therapeutics, Inc. - Common Stock (ALLO) was held by
170 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
115,525,619 shares.
The largest 10 holders included
TPG GP A, LLC, BlackRock Inc., STATE STREET CORP, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, PRIMECAP MANAGEMENT CO/CA/, Capital International Investors, JPMORGAN CHASE & CO, EcoR1 Capital, LLC, and CITADEL ADVISORS LLC.
This page lists
172
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.